Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Page 1
Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.
Cattran DC, Floege J, Coppo R. Cattran DC, et al. Kidney Int Rep. 2023 Sep 22;8(12):2515-2528. doi: 10.1016/j.ekir.2023.09.020. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106572 Free PMC article. Review.
Multiple novel therapies are likely to be approved in the short-term, but clinicians lack the tools to identify patients most likely to benefit from specific treatments at the right time. ...
Multiple novel therapies are likely to be approved in the short-term, but clinicians lack the tools to identify patients most likely …
Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis.
Jauhal A, Reich HN, Hladunewich M, Barua M, Hansen BE, Naimark D, Troyanov S, Cattran DC; Toronto Glomerulonephritis Registry group. Jauhal A, et al. Among authors: cattran dc. Nephrol Dial Transplant. 2023 Mar 31;38(4):950-960. doi: 10.1093/ndt/gfac238. Nephrol Dial Transplant. 2023. PMID: 35948275 Free PMC article.
BACKGROUND: Although the clinical benefit of obtaining a remission in proteinuria in nephrotic patients with focal segmental glomerulosclerosis (FSGS) is recognized, the long-term value of maintaining it and the impact of relapses on outcome are not well described. ...CONC …
BACKGROUND: Although the clinical benefit of obtaining a remission in proteinuria in nephrotic patients with focal segmental glomerulosclero …
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.
Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH. Thompson A, et al. Among authors: cattran dc. Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11. Clin J Am Soc Nephrol. 2019. PMID: 30635299 Free PMC article.
The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment's effect on long-term kidney outcomes in IgAN and be used as a basis for approval. ...
The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment …
Membranous nephropathy: integrating basic science into improved clinical management.
Cattran DC, Brenchley PE. Cattran DC, et al. Kidney Int. 2017 Mar;91(3):566-574. doi: 10.1016/j.kint.2016.09.048. Epub 2017 Jan 5. Kidney Int. 2017. PMID: 28065518 Free article. Review.
Immunostaining of biopsy specimens has further detected either PLA2R or THSD7A antigen in the deposited immune complexes in 5% to 10% of cases autoantibody seronegative at the time of biopsy. Therefore, the term IMN should now be superseded by the term primary or au …
Immunostaining of biopsy specimens has further detected either PLA2R or THSD7A antigen in the deposited immune complexes in 5% to 10% of cas …
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
Cattran DC, Kim ED, Reich H, Hladunewich M, Kim SJ; Toronto Glomerulonephritis Registry group. Cattran DC, et al. J Am Soc Nephrol. 2017 Mar;28(3):995-1003. doi: 10.1681/ASN.2015111262. Epub 2016 Oct 18. J Am Soc Nephrol. 2017. PMID: 27756808 Free PMC article.
Although change in proteinuria has been proposed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability in proteinuria levels and lag between these changes and acceptable end points, such as ESRD, has limited its utility. ...This study validate …
Although change in proteinuria has been proposed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability …
The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.
Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC. Hogan MC, et al. Among authors: cattran dc. Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12. Kidney Int. 2016. PMID: 27528553 Free PMC article.
However an estimating equation was developed to derive 24-hour urine protein excretion from random urine protein creatinine ratio values with improved precision. The long-term prognostic value of log(10)-transformed random protein creatinine ratios values requires future s …
However an estimating equation was developed to derive 24-hour urine protein excretion from random urine protein creatinine ratio values wit …
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group. Fervenza FC, et al. Among authors: cattran dc. Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12. Nephron. 2015. PMID: 26087670 Clinical Trial.
The membranous nephropathy trial of rituximab (MENTOR) hypothesizes that B-cell targeting with rituximab is non-inferior to CSA in inducing long-term remission of proteinuria. METHODS AND DESIGN: Patients with idiopathic membranous nephropathy, proteinuria 5 g/24 h, and a …
The membranous nephropathy trial of rituximab (MENTOR) hypothesizes that B-cell targeting with rituximab is non-inferior to CSA in inducing …
Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.
Thompson A, Cattran DC, Blank M, Nachman PH. Thompson A, et al. Among authors: cattran dc. J Am Soc Nephrol. 2015 Dec;26(12):2930-7. doi: 10.1681/ASN.2015010091. Epub 2015 Jun 15. J Am Soc Nephrol. 2015. PMID: 26078365 Free PMC article.
This manuscript evaluates complete remission (CR) and partial remission (PR) of proteinuria as surrogate end points for a treatment effect on ESRD in patients with primary MN with heavy proteinuria. CR is associated with a low relapse rate and excellent long-term renal sur …
This manuscript evaluates complete remission (CR) and partial remission (PR) of proteinuria as surrogate end points for a treatment effect o …
Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Irazabal MV, et al. Among authors: cattran dc. Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17. Nephrol Dial Transplant. 2013. PMID: 22987142 Free PMC article.
CONCLUSIONS: The results suggest that in patients with MN, quantification of low-, medium- and high-molecular-weight urinary proteins may be associated with rate of response to RTX, but do not correlate with longer term outcomes....
CONCLUSIONS: The results suggest that in patients with MN, quantification of low-, medium- and high-molecular-weight urinary proteins may be …
35 results